Patents by Inventor Kejian Zhang
Kejian Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11921412Abstract: A method for manufacturing a projection screen and a projection screen are provided. The method includes: preparing a substrate; under a first preparation condition, forming a reflective layer by vacuum plating above the substrate; and under a second preparation condition, forming a diffusion layer by the vacuum plating on the reflective layer. The second preparation condition is different from the first preparation condition, and a sputtering power in the second preparation condition is higher than a sputtering power in the first preparation condition.Type: GrantFiled: November 18, 2019Date of Patent: March 5, 2024Assignee: APPOTRONICS CORPORATION LIMITEDInventors: Hongxiu Zhang, Wei Sun, Kejian Cui, Yi Li
-
Patent number: 11827909Abstract: Provided are a proline hydroxylase and uses thereof. The proline hydroxylase comprises having the amino acid sequence of SEQ ID NO: 2 with the exception of a mutation of one or more amino acids; wherein the mutation of one or more amino acids must comprises E27K, and the mutation of one or more amino acids selected from the group consisting of: H14R, L16N, T25R, F26L, E27K, D30S, S33N, E34N, E34G, E34L, E34S, E34D, Y35W, Y35K, S37W, S37F, S37E, S37N, S37T, S37C, W40F, K41E, D54G, H55Q, S57L, I58T, I58Y, I58A, I58R, I58V, I58S, I58C, K86P, T91A, F95Y, C97Y, I98V, K106V, K106T, K106Q, F111S, K112E, K112R, S154A, K162E, L166M, I118F, I118V, I118R, H119R, H119F, I120V, K123D, K123N, K123Q, K123S, K123I, K123T, T130N, D134G, V135K, N165H, D173G, K209R, I223V and S225A, and having proline hydroxylase activity.Type: GrantFiled: December 10, 2020Date of Patent: November 28, 2023Assignees: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD., ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD., TIANJIN ASYMCHEM PHARMACEUTICALS CO., LTD., ASYMCHEM LABORATORIES (FUXIN) CO., LTD., JILIN ASYMCHEM LABORATORIES CO., LTD.Inventors: Hao Hong, Gage James, Jiangping Lu, Na Zhang, Wenyan Yu, Fang Liu, Yanjun Li, Xin Huang, Juan Gao, Kejian Zhang, Yulei Ma, Junlu Wei
-
Patent number: 11746377Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.Type: GrantFiled: June 19, 2020Date of Patent: September 5, 2023Assignee: CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Senthilkumar Sadhasivam, Vidya Chidambaran, John McAuliffe, Kejian Zhang, Jaroslaw Meller, Cynthia A. Prows, Tsuyoshi Fukuda
-
Patent number: 11702640Abstract: The present application relates to the technical field of genetic engineering, and provides a monooxygenase mutant, a preparation method and application thereof. The monooxygenase mutant has any one of the amino acid sequences shown in (I) and (II): (I) an amino acid sequence having at least 80% identity with the amino acid sequence shown in SEQ ID NO. 1; and (II) an amino acid sequence obtained by modifying, substituting, deleting, or adding one or several amino acids to the amino acids at 23 to 508 positions of the amino acid sequence shown in SEQ ID NO. 1, the substituting referring to a substitution of 1 to 34 amino acids, wherein the mutant has the activity of monooxygenase.Type: GrantFiled: February 8, 2018Date of Patent: July 18, 2023Assignee: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.Inventors: Hao Hong, James Gage, Jiangping Lu, Xuecheng Jiao, Na Zhang, Rui Li, Kejian Zhang, Yu Zhang
-
Patent number: 11603521Abstract: Provided is an amino acid dehydrogenase mutant. The amino acid sequence of the mutant is obtained by mutating the amino acid sequence shown in SEQ ID NO:1. The mutation includes at least one of the following mutation sites: 64th, 94th, 133rd, 137th, 148th, 168th, 173rd, 183 rd, 191st, 207th, 229th, 248th, 255th and 282nd sites; or the amino acid sequence of the amino acid dehydrogenase mutant is an amino acid sequence having the mutation sites in the mutated amino acid sequence and having a 80% or more homology with the mutated amino acid sequence. The mutant enzyme activity is more than 50 times higher than that of wild amino acid dehydrogenase, and the enzyme specificity is also correspondingly improved.Type: GrantFiled: August 17, 2018Date of Patent: March 14, 2023Assignee: ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTDInventors: Hao Hong, Gage James, Jiangping Lu, Na Zhang, Xuecheng Jiao, Rui Li, Kejian Zhang, Yu Zhang, Yiming Yang
-
Patent number: 11597978Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.Type: GrantFiled: April 16, 2020Date of Patent: March 7, 2023Assignee: CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Senthilkumar Sadhasivam, Vidya Chidambaran, John McAuliffe, Kejian Zhang, Jaroslaw Meller, Cynthia A. Prows, Tsuyoshi Fukuda
-
Publication number: 20230002795Abstract: Provided is a ketoreductase mutant and a method for producing chiral alcohol using the same. The ketoreductase mutant has a sequence with amino acid mutations in the sequence shown in SEQ ID NO:1. The mutation sites include at least one of the following positions: 6th position, 21st position, 42nd position, 58th position, 61st position, 76th position, 87th position, 94th position, 96th position, 108th position, 113th position, 117th position, 144th position, 146th position, 147th position, 149th position, 151st position, 152nd, 156th position, 165th position, 177th position, and 198th position.Type: ApplicationFiled: June 13, 2019Publication date: January 5, 2023Inventors: Hao HONG, James GAGE, Yi XIAO, Na ZHANG, Xuecheng JIAO, Kejian ZHANG, Yiming YANG
-
Publication number: 20220403421Abstract: Disclosed are a ketoreductase mutant and a method for producing a chiral alcohol. The ketoreductase mutant has an amino acid sequence obtained by the mutation of the amino acid sequence shown in SEQ ID NO: 1, and the mutation includes a mutation siteK200H. In the present disclosure, the mutant obtained by mutation takes a ketone compound as a raw material, the chiral alcohol may be efficiently produced by stereoselective reduction, and the stability is greatly improved, which is suitable for popularization and application to the industrial production of the chiral alcohol.Type: ApplicationFiled: November 7, 2019Publication date: December 22, 2022Inventors: Hao HONG, Gage JAMES, Yi HSIAO, Na ZHANG, Xuecheng JIAO, Kejian ZHANG, Yiming YANG, Xiang WANG, Yanqing ZHANG
-
Patent number: 11407982Abstract: Disclosed are transaminase mutants and use thereof. The amino acid sequence of the transaminase mutant is obtained by the mutation of the amino acid sequence as shown in SEQ ID NO: 1, and the mutation at least comprises one of the following mutation sites: the 19-th site, the 41-th site, the 43-th site, the 72-th site, the 76-th site, the 92-th site, the 107-th site, the 125-th site, the 132-th site, the 226-th site, the 292-th site, the 295-th site, the 308-th site, and the 332-th site; and the 19-th site is mutated into a serine, the 41-th site is mutated into a serine, the 43-th site is mutated into an asparagine, a glycine in the 72-th site is mutated into a leucine, etc.; or the amino acid sequence of the transaminase mutant has the mutation sites in the mutanted amino acid sequence, and has more than 80% homology to the mutanted amino acid sequence.Type: GrantFiled: November 6, 2017Date of Patent: August 9, 2022Assignee: ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTDInventors: Hao Hong, Gage James, Jiangping Lu, Xuecheng Jiao, Na Zhang, Rui Li, Kejian Zhang
-
Publication number: 20220195247Abstract: Curable pressure sensitive adhesive tapes comprise: a) a pressure sensitive adhesive polymer; b) particles of encapsulated first epoxy resin (microcapsules) mixed into the pressure sensitive adhesive polymer; and c) a first epoxy curative. In some embodiments, the first epoxy curative is blended into the pressure sensitive adhesive. In other embodiments, the first epoxy curative is the pressure sensitive adhesive polymer. In some embodiments, the first epoxy curative may be an adduct of a second epoxy curative and a second epoxy resin in a ratio of at least 2:1 second epoxy curative to second epoxy resin. The particles of encapsulated first epoxy resin comprise a core of first epoxy resin within a shell comprising an organic polymer, and optionally a layer of oil-in-water Pickering emulsifier particles borne on a surface of the shells. Typically, the tape may be cured to form a structural bond between adherends.Type: ApplicationFiled: March 24, 2020Publication date: June 23, 2022Inventors: Jian Li, Catherine E. Bardeau, Frank A. Brandys, Kejian Zhang, Weixing Hou
-
Publication number: 20220002683Abstract: An amino acid sequence of the monooxygenase mutant is obtained by mutation of an amino acid sequence shown in SEQ ID NO: 1, and the mutation at least includes one of the following mutation sites: 45-th site, 95-th site, 106-th site, 108-th site, 114-th site, 186-th site, 190-th site, 191-th site, 249-th site, 257-th site, 393-th site, 436-th site, 499-th site, 500-th site, 501-th site, 503-th site, 504-th site, 559-th site, and 560-th site.Type: ApplicationFiled: November 5, 2018Publication date: January 6, 2022Inventors: Hao HONG, Gage JAMES, Jiangping LU, Xuecheng JIAO, Na ZHANG, Kejian ZHANG, Rui LI, Yu ZHANG, Yiming YANG
-
Patent number: 11174528Abstract: An oil-immersion quenching cooling precursor and an oil-immersion quenching cooling method includes an axle-type workpiece or a workpiece that has sections in an axle form. Several separation rings are arranged on the workpiece in the axial direction to separate the axle-type workpiece or the workpiece that has sections in an axle form into a plurality of sections before oil-immersion quenching cooling. In the method, there is a cutting procedure before a quenching cooling procedure. Several separation rings distributed in the axial direction are reserved outside a dimension required for the workpiece. sections before oil-immersion quenching cooling. In the method, there is a cutting procedure before a quenching cooling procedure. Several separation rings distributed in the axial direction are reserved outside a dimension required for the workpiece.Type: GrantFiled: June 20, 2016Date of Patent: November 16, 2021Assignee: BEIJING HUALI FINE CHEMICAL CO., LTD.Inventors: Kejian Zhang, Shui Wang, Xuezhi Hao, Shengdong Ge
-
Publication number: 20210292717Abstract: Provided is an amino acid dehydrogenase mutant. The amino acid sequence of the mutant is obtained by mutating the amino acid sequence shown in SEQ ID NO:1. The mutation includes at least one of the following mutation sites: 64th, 94th, 133rd, 137th, 148th, 168th, 173rd, 183 rd, 191st, 207th, 229th, 248th, 255th and 282nd sites; or the amino acid sequence of the amino acid dehydrogenase mutant is an amino acid sequence having the mutation sites in the mutated amino acid sequence and having a 80% or more homology with the mutated amino acid sequence. The mutant enzyme activity is more than 50 times higher than that of wild amino acid dehydrogenase, and the enzyme specificity is also correspondingly improved.Type: ApplicationFiled: August 17, 2018Publication date: September 23, 2021Inventors: Hao Hong, Gage James, Jiangping Lu, Na Zhang, Xuecheng Jiao, Rui Li, Kejian Zhang, Yu Zhang, Yiming Yang
-
Publication number: 20210095262Abstract: Provided are a proline hydroxylase and uses thereof. The proline hydroxylase comprises having the amino acid sequence of SEQ ID NO: 2 with the exception of a mutation of one or more amino acids; wherein the mutation of one or more amino acids must comprises E27K, and the mutation of one or more amino acids selected from the group consisting of: H14R, L16N, T25R, F26L, E27K, D30S, S33N, E34N, E34G, E34L, E34S, E34D, Y35W, Y35K, S37W, S37F, S37E, S37N, S37T, S37C, W40F, K41E, D54G, H55Q, S57L, I58T, I58Y, I58A, I58R, I58V, I58S, I58C, K86P, T91A, F95Y, C97Y, I98V, K106V, K106T, K106Q, F111S, K112E, K112R, S154A, K162E, L166M, I118F, I118V, I118R, H119R, H119F, I120V, K123D, K123N, K123Q, K123S, K123I, K123T, T130N, D134G, V135K, N165H, D173G, K209R, I223V and S225A, and having proline hydroxylase activity.Type: ApplicationFiled: December 10, 2020Publication date: April 1, 2021Inventors: Hao HONG, Gage JAMES, Jiangping LU, Na ZHANG, Wenyan YU, Fang LIU, Yanjun LI, Xin HUANG, Juan GAO, Kejian ZHANG, Yulei MA, Junlu WEI
-
Patent number: 10961516Abstract: Provided are a proline hydroxylase and uses thereof. The proline hydroxylase comprises (a) a protein having the amino acid sequence as shown in SEQ ID NO: 2; (b) a protein having an amino acid sequence of SEQ HD NO: 2 with a mutation of one or more amino acids and having a proline hydroxylase activity; or (c) a protein retaining the mutation of one or more amino acids as in (b), and having the proline hydroxylase activity and having at least 78% homology with the amino acid sequence of the protein in (b). Protein having the amino acid sequence as shown in SEQ HD NO: 2 and mutants obtained by genetically engineering have higher catalytic specificity or significantly increased catalytic activity when compared to proline hydroxylases in prior art.Type: GrantFiled: November 4, 2016Date of Patent: March 30, 2021Assignees: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD., ASYMCHEM LIFE SCIENCES (TIANJIN) CO., LTD., TIANJIN ASYMCHEM PHARMACEUTICALS CO., LTD., ASYMCHEM LABORATORIES (FUXIN) CO., LTD., JILIN ASYMCHEM LABORATORIES CO., LTD.Inventors: Hao Hong, Gage James, Jiangping Lu, Na Zhang, Wenyan Yu, Fang Liu, Yanjun Li, Xin Huang, Juan Gao, Kejian Zhang, Yulei Ma, Junlu Wei
-
Publication number: 20210024904Abstract: Disclosed are transaminase mutants and use thereof. The amino acid sequence of the transaminase mutant is obtained by the mutation of the amino acid sequence as shown in SEQ ID NO: 1, and the mutation at least comprises one of the following mutation sites: the 19-th site, the 41-th site, the 43-th site, the 72-th site, the 76-th site, the 92-th site, the 107-th site, the 125-th site, the 132-th site, the 226-th site, the 292-th site, the 295-th site, the 308-th site, and the 332-th site; and the 19-th site is mutated into a serine, the 41-th site is mutated into a serine, the 43-th site is mutated into an asparagine, a glycine in the 72-th site is mutated into a leucine, etc.; or the amino acid sequence of the transaminase mutant has the mutation sites in the mutanted amino acid sequence, and has more than 80% homology to the mutanted amino acid sequence.Type: ApplicationFiled: November 6, 2017Publication date: January 28, 2021Applicant: Asymchem Life Science (Tianjin) Co., LtdInventors: Hao HONG, Gage JAMES, Jiangping LU, Xuecheng JIAO, Na ZHANG, Rui LI, Kejian ZHANG
-
Publication number: 20200362318Abstract: The present application relates to the technical field of genetic engineering, and provides a monooxygenase mutant, a preparation method and application thereof. The monooxygenase mutant has any one of the amino acid sequences shown in (I) and (II): (I) an amino acid sequence having at least 80% identity with the amino acid sequence shown in SEQ ID NO. 1; and (II) an amino acid sequence obtained by modifying, substituting, deleting, or adding one or several amino acids to the amino acids at 23 to 508 positions of the amino acid sequence shown in SEQ ID NO. 1, the substituting referring to a substitution of 1 to 34 amino acids, wherein the mutant has the activity of monooxygenase.Type: ApplicationFiled: February 8, 2018Publication date: November 19, 2020Inventors: Hao HONG, James GAGE, Jiangping LU, Xuecheng JIAO, Na ZHANG, Rui LI, Kejian ZHANG, Yu ZHANG
-
Publication number: 20200340061Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.Type: ApplicationFiled: June 19, 2020Publication date: October 29, 2020Inventors: Senthikumar Sadhasivam, Vidya Chidambaran, John McAuliffe, Kejian Zhang, Jaroslaw Meller, Cynthia A. Prows, Tsuyoshi Fukuda
-
Publication number: 20200318194Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.Type: ApplicationFiled: June 19, 2020Publication date: October 8, 2020Inventors: Senthikumar Sadhasivam, Vidya Chidambaran, John McAuliffe, Kejian Zhang, Jaroslaw Meller, Cynthia A. Prows, Tsuyoshi Fukuda
-
Publication number: 20200308648Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.Type: ApplicationFiled: April 16, 2020Publication date: October 1, 2020Inventors: Senthilkumar Sadhasivam, Vidya Chidambaran, John McAuliffe, Kejian Zhang, Jaroslaw Meller, Cynthia A. Prows, Tsuyoshi Fukuda